ClinicalTrials.gg

Hepatitis B, Chronic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 896 studies for Hepatitis B, Chronic across more than 10 countries. 153 are recruiting or about to start. 843 of them are mainly about Hepatitis B, Chronic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 1,210 studies for Hepatitis B, Chronic. How that becomes 895 here

This page counts the studies the registry files under Hepatitis B, Chronic, and those it files under no condition that list Hepatitis B, Chronicthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,210Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −16List Hepatitis B, Chronic as a condition, but the registry did not file them under itMost often written as “Hepatitis B, Chronic (CHB)” (3), “Hepatitis B Chronic Infection” (2), and “HBe Negative Chronic Hepatitis B” (1). The registry filed them under other conditions only, most often Hepatitis B (11) and Bronchiolitis Obliterans Syndrome (4).
  3. −299Match it another way167 name it in the title, 3 in a keyword, and 129 by a synonym or other text the search reads.
  4. 895The count on this page30 of them list Hepatitis B, Chronic in their own words; the registry filed them under no condition.

Status

Completed
407
Status unknown
210
Recruiting
97
Terminated
61
Not yet recruiting
50
Active, not recruiting
41

Phase

Phase 4
197
Phase 2
194
Phase 1
151
Phase 3
89
Early Phase 1
7

Where

China
375
Korea, Republic of
149
United States
112
Taiwan
99
Hong Kong
88
New Zealand
82

Who develops what

Add Hepatitis B, Chronic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 32 programs from 23 companies, 32 with this as their studies’ main aim; 5 with a live phase 3 study; 10 primary completions in the next 12 months. Compare Ausper Biopharma, Xiamen Amoytop Biotech and GNI Group here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
TenofovirRecent, repeated
Evidence
  • NCT07797231 · Sino Biopharmaceutical Limited · Phase 3 · live · background · “Tenofovir Disoproxil Fumarate Tablets” · registered Aug 2026
  • NCT06963710 · Aligos Therapeutics · Phase 2 · live · comparator · “TDF” · registered Apr 2025
  • NCT06150014 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Tenofovir disoproxil fumarate tablet” · registered Nov 2023
  • NCT05612581 · Vir Biotechnology, Inc. · Phase 2 · background · “TDF” · registered Nov 2022
  • NCT05275023 · Johnson & Johnson · Phase 2 · background · “Tenofovir Disoproxil” · registered Mar 2022
Gilead Sciences38% of its industry studiesUS: off-patent, 27 generics marketedEU: off-patent, 2 generics authorized56 studies
entecavirRecent, repeated
Evidence
  • NCT07797231 · Sino Biopharmaceutical Limited · Phase 3 · live · background · “Entecavir dispersible tablets” · registered Aug 2026
  • NCT06990776 · Sino Biopharmaceutical Limited · Phase 2 · background · “Entecavir dispersible tablets” · registered May 2025
  • NCT06150014 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Entecavir dispersible tablets” · registered Nov 2023
  • NCT05484466 · Shanghai Zhimeng Biopharma, Inc. · Phase 2 · background · “Baraclude” · registered Jul 2022
  • NCT05275023 · Johnson & Johnson · Phase 2 · background · “Entecavir” · registered Mar 2022
Bristol-Myers Squibb60% of its industry studiesUS: off-patent, 8 generics marketedEU: off-patent, 2 generics authorized35 studies
tenofovir alafenamideRecent, repeated
Evidence
  • NCT07797231 · Sino Biopharmaceutical Limited · Phase 3 · live · background · “Tenofovir Alafenamide Fumarate Tablets” · registered Aug 2026
  • NCT06150014 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Tenofovir alafenamide fumarate tablet” · registered Nov 2023
  • NCT05275023 · Johnson & Johnson · Phase 2 · background · “Tenofovir Alafenamide” · registered Mar 2022
  • NCT05244057 · Shanghai HEP Pharmaceutical Co., Ltd. · Phase 2 · background · “Tenofovir Alafenamide Tablets” · registered Feb 2022
  • NCT05005507 · Johnson & Johnson · Phase 2 · background · “TAF” · registered Aug 2021
Gilead Sciences75% of its industry studiesUS: Gilead Sciences (FDA 2016)EU: Gilead Sciences (EMA 2017)34 studies

16 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
neracorvir☆ Track2 live phase-3 studies: NCT07588009, NCT07090759Fujian Akeylink Biotechnology Co., Ltd.
Hepatitis B Virus Antisense Oligonucleotide AHB-137☆ Track1 live phase-3 study: NCT07246889Ausper Biopharma Co., Ltd.
ZM-H1505R☆ Track1 live phase-3 study: NCT07095855Shanghai Zhimeng Biopharma, Inc.
HRS-5635☆ Track1 live phase-3 study: NCT07606950Jiangsu HengRui Medicine Co., Ltd.
TQA3605☆ Track1 live phase-3 study: NCT07797231Sino Biopharmaceutical Limited

The 5 in phase 3 with the nearest primary completion, of 32 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (10)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 1 Dec 2026 est.neracorvir · Fujian Akeylink Biotechnology Co., Ltd. · Phase 3 main aimNCT07090759 To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment — primary endpoint: Proportion of participants with serum Hepatitis B Virus (HBV) DNA · 526 enrolled
  • 12 Dec 2026 est.Hepatitis B Virus Antisense Oligonucleotide AHB-137 · Ausper Biopharma Co., Ltd. · Phase 2 main aimNCT07137910 A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) — primary endpoint: Proportion of participants with persistent HBsAg < limit of detection (LOD) and HBV DNA < lower limit of quantification (LLOQ) at the 24th week after all treatment for CHB was discontinued. · 200 enrolled
  • 18 Dec 2026 est.Hepatitis B Virus Antisense Oligonucleotide AHB-137 · Ausper Biopharma Co., Ltd. · Phase 3 main aimNCT07246889 Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) — primary endpoint: Proportion of participants with persistent HBsAg < limit of detection (LOD) and HBV DNA < lower limit of quantification (LLOQ) at the 24th week after all treatment for CHB was discontinued · 577 enrolled

7 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hepatitis B, Chronic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 6 open · Reverse transcriptase inhibitors 94

Coming up

59studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger. 11 (11%) take children under 18. 3 (3%) are for women only and 0 (0%) for men only; 13 (13%) take healthy volunteers.

Recruiting studies that take each age, of 97
AgeWomenMen
108 (8%)7 (7%)
1887 (90%)86 (89%)
3094 (97%)91 (94%)
4096 (99%)93 (96%)
5093 (96%)92 (95%)
6579 (81%)78 (80%)
7540 (41%)39 (40%)
8533 (34%)32 (33%)

Across all 896 studies, recruiting or not: 67% stop at 75 or younger and 47% at 65; 11% take children; 3% are for women only and 1% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hepatitis B, Chronic studies take

Of 87 phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 23 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 116 mo6–27 · 81 studies15 mo5–26 · 73 studies—
Phase 223 mo16–41 · 87 studies22 mo15–39 · 75 studies—
Phase 333 mo21–47 · 24 studies——
Phase 444 mo30–64 · 63 studies—47 mo40–83 · 46 studies
Interventional, no phase44 mo21–121 · 42 studies——
Observational55 mo31–99 · 71 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 896. Browse all 896 → or search them.